semaglutide novo nordisk patent Ozempic's problem: how lost control of a blockbuster drug. π Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite What is the patent landscape
Description
Healthcare professionals recommend maintaining adequate calorie intake to prevent nutritional deficiencies, muscle loss, and metabolic complications despite appetite suppression
Gastrointestinal side effects, particularly diarrhea, occur in approximately 20-25% of semaglutide users during the first weeks of treatment
Because of these effects, medical supervision helps ensure treatment remains both safe and effective
Many people struggle to achieve a healthy weight
Feng X (Snow), Farej R, Dean BB, et al
